This recent BioCentury Inc. article highlights one of the potential consequences of the hashtag#InflationReductionAct: tighter formularies for Part D drugs as plans look for mechanisms to manage their increased liability under the redesigned Part D benefit beginning in 2025.
read full article ›The snark is strong with PhRMA. In a new ad campaign featuring smarmy health plan and PBM “suits,” the industry trade group points a very big finger at healthcare middlemen. But you don’t have to be a communications Jedi Master to see how this kind of messaging could move quickly from being seen as tongue-in-cheek to insert foot-in-mouth.
read full article ›And just like that ...one day after it released its excoriating report, the FTC apparently plans to file a lawsuit against the 3 big PBMs for their rebate practices linked to insulin and other medicines according to The Wall Street Journal.
read full article ›The title of the FTC’s interim report on PBM practices, “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies,” says it all: these organizations are once again on the hot seat.
read full article ›On the last news day before the 4th of July holiday break in the US, Lilly's donanemab (brand name Kisunla) gets a positive nod from FDA. Pricing for one year of therapy is estimated to be $32K, but patients can stop therapy early if imaging shows significant removal of amyloid plaques.
read full article ›There’s no question that compliance is crucial when considering additional financial assistance for patients. Any doubts, look no further than the recent notice from Teva regarding its ongoing US Department of Justice lawsuit, which alleges that the pharma company directed patients to specific charitable foundations that helped cover Medicare patients’ out-of-pocket drug costs to drive prescriptions of Copaxone, its multiple sclerosis drug.
read full article ›A topic near and dear to our hearts. Success for biopharmas will increasingly depend on a deep understanding of pricing strategy and market access and an ability to clearly and simply communicate product value. Elevating this issue to the C-suite - and the board - is a must.
read full article ›